Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenserine.

Jochen Klein1

  • 1University of Frankfurt College of Pharmacy, Biocenter N260, Frankfurt, Germany. Klein@em.uni-frankfurt.de

Expert Opinion on Investigational Drugs
|June 28, 2007
PubMed
Summary
This summary is machine-generated.

Phenserine, an Alzheimer's drug, reduces beta-amyloid peptide formation by inhibiting acetylcholinesterase and modulating APP translation. Its enantiomers, phenserine and posiphen, offer potential therapeutic strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Central Cholinergic Synapse: A Primer.

International journal of molecular sciences·2025
Same author

Acetylcholine and choline in honey bee (Apis mellifera) worker brood food are seasonal and age-dependent.

Scientific reports·2024
Same author

Oxidative stress in rat brain during experimental status epilepticus: effect of antioxidants.

Frontiers in pharmacology·2023
Same author

Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice.

International journal of molecular sciences·2023
Same author

Inhibition of mitochondrial respiration by general anesthetic drugs.

Naunyn-Schmiedeberg's archives of pharmacology·2022
Same author

ß-Hydroxybutyrate Improves Mitochondrial Function After Transient Ischemia in the Mouse.

Neurochemical research·2022

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Phenserine, a physostigmine derivative, inhibits acetylcholinesterase (AChE) and improves cognition in preclinical models.
  • Initial clinical trials for Alzheimer's disease (AD) showed moderate success for phenserine.
  • Phenserine exhibits a dual mechanism of action beyond AChE inhibition.

Purpose of the Study:

  • To investigate phenserine's additional mechanism of action on beta-amyloid precursor protein (APP) expression.
  • To explore the role of phenserine's enantiomers in modulating APP and Abeta formation.
  • To evaluate the therapeutic potential of phenserine and its enantiomers for Alzheimer's disease.

Main Methods:

  • Neuronal cell culture studies to assess APP translation modulation.

Related Experiment Videos

  • In vitro and in vivo experiments to measure beta-amyloid peptide (Abeta) formation.
  • Comparative analysis of phenserine and its enantiomers, (-)-phenserine and (+)-phenserine (posiphen), on AChE inhibition and APP downregulation.

    • Main Results:

    • Phenserine reduces APP translation, likely via interaction with the 5'-untranslated region of the APP gene and iron-responsive elements.
    • This modulation leads to decreased beta-amyloid peptide (Abeta) formation both in vitro and in vivo.
    • (-)-Phenserine is the primary AChE inhibitor, while (+)-phenserine (posiphen) is a weak AChE inhibitor but equally potent in downregulating APP expression.

    Conclusions:

    • Phenserine possesses a unique dual mechanism targeting both AChE and APP translation, reducing Abeta formation.
    • (+)-Posiphen, with its distinct pharmacological profile, shows promise as a therapeutic agent for Alzheimer's disease, potentially in combination with (-)-phenserine.
    • The differential actions of phenserine's enantiomers offer distinct therapeutic avenues for attenuating Alzheimer's disease progression.